|
|
Post by joshuabohinc on Jan 19, 2021 20:47:55 GMT -5
I’m sold. Listen to the last 2 min of today’s presentation. Tyvaso DPI is a game changer. An earlier question by JPM, Ms, Fye, asked why tyvaso didn’t show a quality of life improvement and impact to sell to new population ILD? Dr. Nathan gave a complicated answer. But his response to last question on Tyvaso DPI is the easy answer of how quality of life will improve and the easy sell. Dreamboat is the easy sell to educate, and get thousands of new docs and tens of thousands new patient on Tyvaso.
|
|
|
|
Post by akemp3000 on Jan 19, 2021 21:39:29 GMT -5
I want to see the Dreamboat featured in major new TV commercials for Tyvaso DPI. UTHR has the funds for the marketing push.
|
|
|
|
Post by cppoly on Jan 20, 2021 11:37:00 GMT -5
From the presentation slides,
Significant differences were observed with inhaled treprostinil, including:
– Improvements in NT-proBNP
– Reduction in time to clinical worsening
– Improvements in peak 6MWD at Week 12
– Improvements in trough 6MWD at Week 15
Also goes on to say:
- Inhaled treprostinil resulted in a 42% reduction in NTproBNP when compared to placebo at Week 16 (P<0.001).
- No deleterious effect of inhaled treprostinil on any PFT parameter during the study.
- Median improvement in percent predicted FVC at Week 16 in the inhaled treprostinil group (1%) compared to reduction in the placebo group (-1%).
– Inhaled treprostinil resulted in placebo-corrected improvements in FVC of 28.47 mL and 44.40 mL at Weeks 8 and 16, respectively.
- Percent predicted FVC at Week 8 (1.79%; P=0.01) and Week 16 (1.80%; P=0.03).
– In IPF patients, inhaled treprostinil resulted in placebo-corrected improvements in FVC of 84.52 mL and 168.52 mL at Weeks 8 (n=78) and 16 (n=70), respectively.
Conclusions:
- INCREASE is the largest and most comprehensive study of this patient group to date.
- Patients experienced significant improvements in exercise capacity (6MWD) as early as 8 weeks, with effects sustained throughout the 16-week treatment period.
- Patients demonstrated improvements in other clinically meaningful outcomes, including improvements in NT-proBNP and decreased risk of clinical worsening and exacerbation of underlying lung disease.
- Treatment with inhaled treprostinil was well tolerated.
- No evidence of worsened oxygenation or lung function, allaying V/Q mismatch concerns.
– Evidence of an improvement in FVC.
- Results support an additional treatment avenue and might herald a shift in the clinical management of patients with ILD.
|
|
|
|
Post by harryx1 on Jan 20, 2021 11:42:36 GMT -5
|
|
|
|
Post by mango on Jan 20, 2021 13:10:03 GMT -5
The improvement in FVC is a big deal. This is the first time a treatment has actually improved FVC in a chronic lung disease. Most other treatments and therapies only help halt or slow down the diminishing of FVC.
I’d imagine the results would be even better with Tyvaso DPI.
Specifically, the average FVC value was 28.47 mL higher in the Tyvaso-treated group after eight weeks, and 44.40 mL higher after 16 weeks, poster data show. Similarly, in Tyvaso-treated patients, percent predicted FVC — which assesses FVC measurements based on typical values — also improved at weeks eight and 16.
|
|
|
|
Post by cretin11 on Jan 20, 2021 18:47:46 GMT -5
The improvement in FVC is a big deal. This is the first time a treatment has actually improved FVC in a chronic lung disease. Most other treatments and therapies only help halt or slow down the diminishing of FVC. I’d imagine the results would be even better with Tyvaso DPI. Specifically, the average FVC value was 28.47 mL higher in the Tyvaso-treated group after eight weeks, and 44.40 mL higher after 16 weeks, poster data show. Similarly, in Tyvaso-treated patients, percent predicted FVC — which assesses FVC measurements based on typical values — also improved at weeks eight and 16. Agree, that improvement in FVC is incredibly good news. An amazing result. |
|
|
|
Post by peppy on Jan 20, 2021 19:00:25 GMT -5
The improvement in FVC is a big deal. This is the first time a treatment has actually improved FVC in a chronic lung disease. Most other treatments and therapies only help halt or slow down the diminishing of FVC. I’d imagine the results would be even better with Tyvaso DPI. Specifically, the average FVC value was 28.47 mL higher in the Tyvaso-treated group after eight weeks, and 44.40 mL higher after 16 weeks, poster data show. Similarly, in Tyvaso-treated patients, percent predicted FVC — which assesses FVC measurements based on typical values — also improved at weeks eight and 16. Agree, that improvement in FVC is incredibly good news. An amazing result. This is my favorite slide from the slide deck, harryx1 posted. I stare at where COPD is in relationship  |
|
